(Reuters) -Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
Comments